Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

被引：0
|
作者：
Winer, Eric S. [1 ]
Garcia, Jacqueline S. [2 ]
Stone, Richard M. [1 ]
Wadleigh, Martha [1 ]
Luskin, Marlise R. [1 ]
Stahl, Maximilian [3 ]
Chen, Evan C. [1 ]
Leonard, Rebecca [2 ]
Noyes, Alexis [1 ]
Galinsky, Ilene [2 ]
Deshpande, Rashmi [4 ]
Borderies, Pascal [4 ]
O'Neill, Vincent [4 ]
DeAngelo, Daniel J. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Dana Farber Inst, Boston, MA USA
[4] BioXcel Therapeut, New Haven, CT USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186598
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Odyssey: A First-in-Human Study of the Aldehyde Dehydrogenase (ALDH) Inhibitor Abd-3001 in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    Benajiba, Lina
    Colle, Julien
    Heiblig, Mael
    Loron, Sandrine
    Soret-Dulphy, Juliette
    Berchard, Paul
    Yazir, Muhube
    Basset, Laurent
    Venton, Geoffroy
    Larcher, Marie-Virginie
    De Oliveira, Rafael Daltro
    Fossard, Gaelle
    Martin, Guillaume
    Perez, Mileidys
    Ceylan, Ismael
    Pelletier, Annick
    Kiladjian, Jean-Jacques
    Costello, Regis
    BLOOD, 2024, 144 : 6001 - 6002
  • [32] Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
    Ivana Gojo
    Alexander Perl
    Selina Luger
    Maria R. Baer
    Kelly J. Norsworthy
    Kenneth S. Bauer
    Michael Tidwell
    Stephanie Fleckinger
    Martin Carroll
    Edward A. Sausville
    Investigational New Drugs, 2013, 31 : 1217 - 1227
  • [33] Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
    Gojo, Ivana
    Perl, Alexander
    Luger, Selina
    Baer, Maria R.
    Norsworthy, Kelly J.
    Bauer, Kenneth S.
    Tidwell, Michael
    Fleckinger, Stephanie
    Carroll, Martin
    Sausville, Edward A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1217 - 1227
  • [34] Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Tang, Man Wai
    van der Tuin, Deborah
    Aydin, Mesire
    Heijmans, Jarom
    van de Loosdrecht, Arjan A.
    Meijer, Ellen
    Rutten, Caroline E.
    Wondergem, Marielle
    Janssen, Jeroen J. W. M.
    Donker, Marjolein L.
    Hazenberg, Mette D.
    Zweegman, Sonja
    Biemond, Bart J.
    De Leeuw, David C.
    Nur, Erfan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (04) : 620 - 625
  • [35] Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Cortes, Jorge
    Ravandi, Farhad
    Plunkett, William
    Gandhi, Varsha
    Faderl, Stefan
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan
    Konopleva, Marina
    Brandt, Mark
    Huang, Xuelin
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (04): : 244 - 251
  • [36] A Phase 1-2 Study of a Farnesyltransferase Inhibitor, Tipifarnib, Combined With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Jabbour, Elias
    Kantarjian, Hagop
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Verstovsek, Srdan
    O'Brien, Susan
    Faderl, Stefan
    Thomas, Deborah A.
    Wright, John J.
    Cortes, Jorge
    CANCER, 2011, 117 (06) : 1236 - 1244
  • [37] A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study
    Buckley, Sarah A.
    Percival, Mary-Elizabeth
    Othus, Megan
    Halpern, Anna B.
    Huebner, Emily M.
    Becker, Pamela S.
    Shaw, Carole
    Shadman, Mazyar
    Walter, Roland B.
    Estey, Elihu H.
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 1023 - 1029
  • [38] Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome
    Mabrey, Frances Linzee
    Gardner, Kelda M.
    Dorcy, Kathleen Shannon
    Perdue, Andrea
    Smith, Heather A.
    Davis, Alicyn M.
    Hammer, Cody
    Rizzuto, Donelle
    Jones, Sunny
    Quach, Kim
    Scott, Bart L.
    Hendrie, Paul C.
    Percival, Mary-Elizabeth M.
    Walter, Roland B.
    Appelbaum, Frederick R.
    Estey, Elihu H.
    Becker, Pamela S.
    BLOOD ADVANCES, 2020, 4 (04) : 611 - 616
  • [39] A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated on Versus Off Study
    Buckley, Sarah A.
    Percival, Mary-Elizabeth M.
    Othus, Megan
    Halpern, Anna B.
    Huebner, Emily M.
    Shaw, Carole
    Hendrie, Paul C.
    Shadman, Mazyar
    Becker, Pamela S.
    Walter, Roland B.
    Estey, Elihu H.
    BLOOD, 2016, 128 (22)
  • [40] A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated On versus Off Study
    Percival, Mary-Elizabeth
    Buckley, Sarah
    Othus, Megan
    Halpern, Anna
    Huebner, Emily
    Becker, Pamela
    Shaw, Carole
    Shadman, Mazyar
    Walter, Roland
    Estey, Elihu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S281 - S281
12345